Tag: Biotech and Pharmaceuticals

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Another alliance of health care and AI signals why pharma stocks should be back in favor

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch

Making U.S. biotech more competitive with China’s could help rare disease patients, experts say

Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference